This study aims to compare the GORE VIABAHN VBX Balloon Expandable Endoprosthesis primary patency to bare metal stenting to evaluate superiority in treating complex iliac occlusive disease with the goal of informing practice guidelines around which modality is best suited for patients with this condition
News | Stents
First Patients Enrolled in the Gore VBX Forward Clinical Study

January 19, 2024 — W. L. Gore & Associates, Inc. announced that the first patients have been enrolled in the Gore VBX ...

Home January 19, 2024
Home
Sumeet Chugh, MD, shown at work in his Cedars-Sinai laboratory
News | Sudden Cardiac Arrest
Smidt Heart Institute Sudden Cardiac Arrest Expert Receives 2024 Distinguished Scientist Award

January 19, 2024 — Heart rhythm expert Sumeet Chugh, MD, associate director of the Smidt Heart Institute at Cedars-Sinai ...

Home January 19, 2024
Home
Abbott's Volt PFA System is designed to overcome limitations of first-generation PFA systems by providing physicians a clearer indication of contact between the Volt PFA Catheter and targeted tissue
News | Atrial Fibrillation
Abbott Announces First Global Procedures in a Clinical Trial of its Volt Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
First in-man experience exceeds expectations, cited as “game changer” for below-the-knee procedures
News | Balloon Catheter
Injectable Angioplasty Balloon Catheter Transforms Peripheral Procedures, Users Report Reduced Equipment and Contrast Needs

January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...

Home January 18, 2024
Home
The American Heart Association has issued a new Policy Statement focused on the need to address structural racism as a central component to reducing cardiovascular disparities across the United States.
News | AHA
American Heart Association New Policy Statement: Addressing Structural Racism Central to Reducing U.S. Cardiovascular Disease Disparities

January 18, 2024 — A new American Heart Association (AHA) policy statement examines the history of structural racism ...

Home January 18, 2024
Home
Physician-researcher David Ouyang, MD, to bring longstanding expertise to Journal focused on artificial intelligence and machine learning
News | Artificial Intelligence
Smidt Heart Institute Expert Named Deputy Editor of NEJM AI

January 17, 2024 — One of the Smidt Heart Institute’s leading experts in artificial intelligence, David Ouyang, MD, has ...

Home January 17, 2024
Home
The application of AI technology in the diagnosis of cardiovascular diseases using coronary CT angiography (CCTA) has gradually deepened
News | Artificial Intelligence
Artificial Intelligence Helps Coronary CT Angiography and Accelerates the Development of Precision Medicine

January 17, 2024 — This review was jointly published by Prof. Long-Jiang Zhang (Department of Radiology, Jinling ...

Home January 17, 2024
Home
Satya Shreenivas, MD, MBA has joined the company as Chief Medical Officer.
News | Heart Failure
Cardiac Dimensions Appoints Satya Shreenivas, MD, as Chief Medical Officer

January 16, 2024 — Cardiac Dimensions, a leader in the development of innovative and minimally invasive treatment ...

Home January 16, 2024
Home
Pilot program to deploy highly portable technology to be rolled out later this year 
News | Artificial Intelligence
Novel AI Platform Matches Cardiologists in Detecting Rheumatic Heart Disease

January 16, 2024 — Artificial intelligence (AI) has the potential to detect rheumatic heart disease (RHD) with the same ...

Home January 16, 2024
Home
Latest technology combines superior catheter design and sustained aspiration to maximize blood clot removal from the coronary vasculature
News | Thrombectomy Devices
Penumbra Launches Indigo System CAT RX Catheter in Europe to Address Acute Coronary Syndrome

January 16, 2024 — Penumbra, Inc., a thrombectomy company, has recently secured CE Mark (Conformité Européenne) for its ...

Home January 16, 2024
Home
A public-private partnership Think Tank
News | Cardiovascular Education
Cardiac Safety Research Consortium Announces Think Tank Program with FDA Regulators, Industry and Academia Focused on Cardiac Remote Monitoring Trials and AI

January 15, 2024 — A public-private partnership Think Tank, scheduled for Feb. 29-March 1, will be presented by the ...

Home January 15, 2024
Home
Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with Pfizer to support the validation and FDA clearance of its AI-based technology for the detection of cardiac amyloidosis.
News | Artificial Intelligence
Ultromics Announces Partnership to Expedite Development of Echo AI Algorithm for Early Detection of Cardiac Amyloidosis

January 15, 2024 — Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the ...

Home January 15, 2024
Home
Larry Goldstein, M.D., chair of the University of Kentucky Department of Neurology.
News | Stroke
Goldstein Selected to Help Lead Statewide Task Force Addressing Heart Disease and Stroke

January 15, 2024 — Larry Goldstein, M.D., chair of the University of Kentucky Department of Neurology, has been selected ...

Home January 15, 2024
Home
Webinar addresses driving efficiency while maintaining diagnostic performance.
News | Computed Tomography (CT)
SPONSORED CONTENT: Webinar on Applying SMART-CT Results to Daily Clinical Practice

HeartFlow is offering a free webinar based on a recent study that measured the ability of the of its roadmap analysis to ...

Home January 15, 2024
Home
ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality (ACM) and frequency of cardiovascular-related hospitalization (CVH)), with a Win Ratio of 1.8 (p<0.0001)
News | Pharmaceuticals
BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

January 12, 2024 — BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Home January 12, 2024
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now